Organ-on-a-chip Company (OOC) CN Bio has expanded its contract research services with the opening of new laboratory facilities at Cambridge Science Park, in the UK. The company has double its laboratory space in response to the increasing demand for OOC services as seen throughout drug discovery and development programmes.
CN Bio states that a rising demand into OOC services demonstrates an acceptance of the technology by pharma and biotech companies within their therapeutic programmes. The company believes this is being fuelled by repeat business, growing interest from regulatory agencies, the technology’s ability to predict clinical outcomes and its potential to replace animal models – especially for the testing of new drug modalities with human-specific modes of action.
Dr Gareth Guenigault, Lead Scientist of CN Bio’s Contract Research Services, said: “This expansion is an exciting next step in the progression of our contract research services offering. As we see increasing awareness within the drug discovery, development and regulatory fields that animal models don’t always get it right, nor are ethically desirable, we are poised to offer solutions that fit researchers’ individual needs. By utilising the power of OOC technology to provide early stage, clinically translatable data across a range of applications, we hope to give customers greater confidence in the success of their projects, in a fraction of the time and cost.”